Nicholls Connie, Chyou Te-Yuan, Nishtala Prasad S
Department of Pharmacy and Pharmacology, University of Bath, Bath, UK.
Department of Biochemistry, University of Otago, Dunedin, Otago, New Zealand.
Int J Risk Saf Med. 2023;34(1):63-73. doi: 10.3233/JRS-210054.
Antimuscarinics are the backbone of the pharmacological management of overactive bladder. Still, concerns have been raised over the nervous system (NS) adverse drug events (AEs) due to their dissimilarities to muscarinic receptor-subtype affinities.
This study aimed to identify the nervous system and gastrointestinal adverse drug events (ADEs) associated with solifenacin use in older adults (≥65 years).
A case/non-case analysis was performed on the reports submitted to the FDA Adverse Event Reporting System (FAERS) between 01/01/2004 and 30/06/2020. Cases were reports for solifenacin with ≥1 ADEs as preferred terms included in the Medical Dictionary of Regulatory Activities (MedDRA) system organ classes 'nervous system' or 'gastrointestinal' disorders. Non-cases were all other remaining reports for solifenacin. The case/non-cases was compared between solifenacin and other bladder antimuscarinics. Frequentist approaches, including the proportional reporting ratio (PRR) and reporting odds ratio (ROR), were used to measure disproportionality. The empirical Bayesian Geometric Mean (EBGM) score and information component (IC) value were calculated using a Bayesian approach. A signal was defined as the lower limit of 95% confidence intervals of ROR ≥ 2, PRR ≥ 2, IC > 0, EBGM > 1, for ADEs with ≥4 reports.
107 MedDRA preferred terms (PTs) comprising 970 ADE reports were retrieved for nervous system disorders associated with solifenacin. For gastrointestinal disorders, 129 MedDRA PTs comprising 1817 ADE reports were retrieved. Statistically significant results were found for 'altered state of consciousness': ROR = 9.71 (2.13-44.35), PRR = 9.69 (2.12-44.2) and IC = 1.29 (0.93-1.66).
The disproportionality reporting of 'altered state of consciousness', a previously unidentified ADE, was unexpected. Further monitoring of this ADE is needed to ensure patient safety, as this could be linked to poor balance and falls in older adults.
抗毒蕈碱药物是膀胱过度活动症药物治疗的主要药物。然而,由于它们与毒蕈碱受体亚型亲和力不同,人们对其神经系统(NS)不良药物事件(AE)表示担忧。
本研究旨在确定老年(≥65岁)患者使用索利那新相关的神经系统和胃肠道不良药物事件(ADE)。
对2004年1月1日至2020年6月30日期间提交给美国食品药品监督管理局不良事件报告系统(FAERS)的报告进行病例/非病例分析。病例是指索利那新的报告,其中至少有1例ADE作为首选术语包含在《监管活动医学词典》(MedDRA)系统器官分类的“神经系统”或“胃肠道”疾病中。非病例是索利那新的所有其他剩余报告。比较了索利那新与其他膀胱抗毒蕈碱药物的病例/非病例情况。采用频率论方法,包括比例报告比(PRR)和报告比值比(ROR)来衡量不均衡性。使用贝叶斯方法计算经验贝叶斯几何均值(EBGM)分数和信息成分(IC)值。对于报告≥4例的ADE,当ROR≥2、PRR≥2、IC>0、EBGM>1时,将信号定义为95%置信区间的下限。
检索到107个MedDRA首选术语(PT),包括970例与索利那新相关的神经系统疾病ADE报告。对于胃肠道疾病,检索到129个MedDRA PT,包括1817例ADE报告。在“意识状态改变”方面发现了具有统计学意义的结果:ROR = 9.71(2.13 - 44.35),PRR = 9.69(2.12 - 44.2),IC = 1.29(0.93 - 1.66)。
“意识状态改变”这一先前未识别的ADE的不均衡报告出乎意料。需要对该ADE进行进一步监测以确保患者安全,因为这可能与老年人平衡能力差和跌倒有关。